Interleukin-23 Subunit P19
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.
GALAXI 1: Continued subcutaneous Tremfya benefits IV induction non-responders with Crohn’s
VANCOUVER, British Columbia — More than 50% of patients with Crohn’s disease who did not achieve clinical response at week 12 to IV Tremfya achieved response at week 48 after continuing subcutaneous therapy, according to a presenter.
Mirikizumab rebounds to win FDA approval as first IL-23p19 agonist for ulcerative colitis
The FDA has approved Eli Lilly’s Omvoh infusion/injection as the “first and only” interleukin-23p19 antagonist for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.
VIVID-1 trial: More than half of mirikizumab users achieve clinical remission in Crohn’s
Topline findings from the phase 3 VIVID-1 trial showed Eli Lilly’s mirikizumab, an interleukin-23p19 antagonist, demonstrated clinical remission and endoscopic response through 52 weeks in adults with moderate to severe Crohn’s disease.
VIDEO: Patients with UC achieve symptomatic remission ‘as early as week 4’ with Tremfya
CHICAGO — In a Healio video exclusive, Jessica R. Allegretti, MD, MPH, explains that nearly 23% of patients with moderate to severe ulcerative colitis achieved clinical remission with Tremfya, compared with less than 10% on placebo.
Guselkumab shows superior long-term efficacy vs. secukinumab based on PASI 90
A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the Psoriasis Area and Severity Index at week 48 than those receiving secukinumab, according to researchers in The Lancet.